Product Reports Resources Pricing Login Book a demo
Thomas Clozel
Person profile

Thomas Clozel

Founded
Septhom, Bioptimus, CURE51 +1 more
Backed
Resilience, Dioxycle, Norbert Health +7 more
Education
Icahn School of Medicine at Mount Sinai

Investments 10

Companies backed, as recorded by Dealroom. Highest company valuations first.

Resilience
Dioxycle
→
Norbert Health
1 recorded funding round · Latest in 2026
→
Altrove
1 recorded funding round · Latest in 2024
→
Grace-technology
1 recorded funding round · Latest in 2025
→
Modern Relay
1 recorded funding round · Latest in 2026
Osium AI
1 recorded funding round · Latest in 2023
Callyope
1 recorded funding round · Latest in 2023
kanji
Patch Biosciences

Companies founded

Currently

Active roles, board seats and partnerships.

Work history

Past roles by Dealroom records.

8400 - The Health Network
Global Expert · 2023
Fragment
Investor · 2023
→
Osium AI
Investor · 2023
Dioxycle
Investor · 2022
→
kanji
Investor · 2022
Resilience
Investor · 2021
Spot
Investor · 2021
→
Patch Biosciences
Investor · 2020
Hôpital Necker-Enfants Malades
2012 – 2014
Paris Diderot University - Paris City University
2009 – 2010
Paris-Cité University
Master 2 Research Track · 2009 – 2010
Weill Cornell Medicine
Research Fellow · 2009 – 2012
Assistance Publique - Hôpitaux de Paris
Intern · 2006 – 2012
Mount Sinai Medical Center
2004 – 2005
Mount Sinai Ventures
2004 – 2005

Education

Icahn School of Medicine at Mount Sinai
until 2006
← All people